Category: 3. Business

  • Stonepeak and Energy Equation Partners Complete Acquisition of Majority Interest in JET

    LONDON & HOUSTON – December 1, 2025 – Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, and Energy Equation Partners (“EEP”), an investment firm with significant expertise in fuel retail, today announced the completion of their previously announced acquisition of a 65% interest in JET Tankstellen Deutschland GmbH (“JET”), a leading fuel retailer in Germany and Austria, from a subsidiary of Phillips 66 (NYSE: PSX), in a transaction valuing the business at an enterprise value of approximately €2.5 billion.

    “We are delighted to complete this acquisition and to partner with Stonepeak and Phillips 66 to take JET to the next level,” said Javed Ahmed, Managing Partner of Energy Equation Partners. “This investment reflects EEP’s commitment to investing in established players in the energy sector who have the potential to make a meaningful impact on the energy transition, and we are excited to work alongside the entire JET team, including its dedicated service station operators, to realize this vision.”

    “The completion of this transaction marks an important step forward for JET,” said Anthony Borreca, Senior Managing Director and Co-Head of Energy at Stonepeak. “With its extensive network of service stations, trusted brand, and the combined expertise that we and EEP bring, JET is well positioned to continue providing reliable service to its customers across Germany and Austria.”

    Akin Gump Strauss Hauer & Feld LLP and Hengeler Mueller served as legal counsel to Stonepeak and EEP. Paul, Weiss, Rifkind, Wharton & Garrison LLP served as financing counsel to Stonepeak and EEP.

    About Stonepeak
    Stonepeak is a leading alternative investment firm specializing in infrastructure and real assets with approximately $80 billion of assets under management. Through its investment in defensive, hard-asset businesses globally, Stonepeak aims to create value for its investors and portfolio companies, with a focus on downside protection and strong risk-adjusted returns. Stonepeak, as sponsor of private equity and credit investment vehicles, provides capital, operational support, and committed partnership to grow investments in its target sectors, which include digital infrastructure, energy and energy transition, transport and logistics, and real estate. Stonepeak is headquartered in New York with offices in Houston, Washington, D.C., London, Hong Kong, Seoul, Singapore, Sydney, Tokyo, Abu Dhabi, and Riyadh. For more information, please visit www.stonepeak.com.

    About Energy Equation Partners
    Energy Equation Partners is an energy specialist investment firm that seeks to invest in companies that are well established in the energy sector and have the potential to play a valuable role in the shift from “brown to green”. Over the past two decades, the principals of EEP have deployed over $10 billion of equity capital across the energy value chain globally and have significant experience in fuel retail.

    Contacts

    For Stonepeak:
    Kate Beers / Maya Brounstein
    corporatecomms@stonepeak.com
    +1 (646) 540-5225

    For Energy Equation Partners:
    Sari Haidar
    sari@energyequationpartners.com
    +44 75 5112 5113

    Continue Reading

  • Barrick Announces Evaluation of an Initial Public Offering of its North American Gold Assets – Barrick Mining

    1. Barrick Announces Evaluation of an Initial Public Offering of its North American Gold Assets  Barrick Mining
    2. Barrick Brief: Barrick Says Would Maintain a “Significant” Controlling Interest in NewCo  MarketScreener
    3. Barrick exploring IPO of North American mines  The Globe and Mail
    4. Barrick stock rises as company explores IPO of North American gold assets  Investing.com
    5. Barrick Brief: Announcing Evaluation of an Initial Public Offering of its North American Gold Assets  MarketScreener

    Continue Reading

  • Keynote speech by SRB Chair Dominique Laboureix at the European Banking Institute Conference “10 Years of SRB – Looking Back and Looking Forward”

    [Check against delivery]

    Future-proofing our crisis management framework

    Dear ladies, dear gentlemen,

    First, let me thank Dr. Thomas Gstädtner and the European Banking Institute for inviting me here today. I would also like to thank Prof. Dr. R. Alexander Lorz for his remarks and the support of the State of Hessen that made this event possible.

    The title of the conference gives it away: this year, we are celebrating the tenth anniversary of the Single Resolution Board (SRB) and of the Single Resolution Mechanism (SRM).

    As we hit this 10-year mark, the moment feels right to pause for a second and ask ourselves – where do we stand and where are we headed?

    And while I would love to dwell on all of the SRB’s achievements in its decade-long existence, I will try to keep that first part short and rather focus on the much more interesting future in a second part. In particular, I would like to focus on how our framework for managing crisis will need to adapt to stay ahead.

    This means:

    • How we keep our crisis management toolkit up to date;

    • How we make our framework more effective and integrated;

    • And finally, how we deal with new risks looming on the horizon.

    But allow me to proceed chronologically.

    1. Where do we stand after 10 years?

    Let me tell you that we have come a long way!

    Bank resolution, I mean its framework and the second pillar of the Banking Union, started from scratch. We started from a theoretical idea of dealing with bank crises to protect financial stability without using public money – that is without “bail-outs”, which had proven so costly during the great financial crisis to the taxpayer.

    Fast forward 10 years to 2025. What a difference the establishment of a crisis management framework makes!

    Over the last decade, the SRM resolved two banks without using one euro of public funds while preserving European financial stability.

    To illustrate my point, let’s travel back in time to 2008 and take, for instance, the Irish situation. 

    So we are in 2008; the financial crisis has spilled over from the US and is gripping Europe. Ireland becomes a victim of this global economic downturn and its lenders are on the brink of collapse. The Irish government has to inject more than 64 billion EUR into the failing banks. That is 64 billion EUR for a population of 4.5 million people at the time – I let you do math of the bailout! 

    Now, let’s move to 2017. After a run on deposits and a liquidity crisis, the ECB declares Banco Popular failing or likely to fail. The SRB together with the NRA resolve the bank, imposing the losses on the shareholders and creditors and sells the bank to another banking group. The cost for the taxpayer was precisely zero, and the impact of financial stability is also zero.

    The impact of a crisis management framework is clear and it is there for everyone to see.

    But there is a second – perhaps more subtle but equally important – contribution of the SRM to financial stability: resolution planning.

    In fact, this day-to-day work is about building resilience into the financial system. We perform our resolution planning task by asking banks to be ready to handle a crisis – that is by developing their “resolvability” in the Resolution Expert’s jargon.

    This is because we consider that an orderly resolution is key to protecting financial stability, the real economy and shielding public finances.

    Let me give you some figures to illustrate this resolvability progress over the past decade:

    • More than EUR 2.6 trillion of loss absorbing capacity built by banks in the Banking Union;

    • EUR 80 billion of Single Resolution Fund ready to be deployed;

    • 150 operational and actionable resolution plans drafted and updated every year for significant and less-significant institutions.

    European banks are more resilient today thanks, in part, to that planning and to the existence of a functioning crisis management framework.

    However, this progress does not mean our “resolvability journey” is over, in fact these elements are only the foundations of our framework.

    In line with our SRM Vision 2028, we have now entered the second, more mature, phase of the SRM’s existence. In terms of resolvability, this means that we are now moving out of the capability-building phase and shifting our focus to testing those capabilities to ensure that these are operational in crisis. We will also be carrying out more on-site inspections to verify banks’ progress across the various resolvability dimensions.

    Now, let me turn to the future and the challenges ahead.

    2. Where are we headed?

    It comes as no surprise to you that there is still a lot to be done.

    Resolving banks will always be complicated, full of surprises and to some extent costly – financial stability does not come for free.

    If we knew precisely how a bank would fail, there would be no need for an elaborate crisis management framework. The reality unfortunately is that we do not have a crystal ball to predict the future!

    This is why, we need to ensure that we are prepared no matter what. This means that our crisis management framework should be able to deal with any type of crisis, no matter its origin.

    To stay ahead, the SRM needs to change and adapt to new developments and challenges. Here’s how, and for this, I will use some key words up-to-date, effective and integrated, agile.

    3, Our resolution toolkit needs to remain up-to-date 

    For resolution to be credible, it is important that our resolution toolkit remains as up-to-date as possible. In Europe – despite European banks’ resilience – this means drawing the lessons from the last crises cases, in particular the 2023 bank turmoil in the US and Switzerland.

    One key lesson from the failures of Silicon Valley Bank and Credit Suisse was that also larger banks could be sold. If a bank is well prepared and the price is right, a buyer can be found. Our resolution strategies need to cater to that possibility and embed a certain degree of optionality.

    This is why, for banks under our remit, we need to develop optionality in our resolution strategies. Concretely, this means being ready to use any resolution tool at our disposal in crisis – both alone or in combination with another tool. To that end, we have already asked banks to develop variant resolution strategies alongside our preferred ones.

    More often than not, the development of variant strategies means the use of transfer tools.

    This refocusing on transfer tools is also backed by experience. Most crisis cases in the last years were resolved with the use of the sale of business or bridge bank tool. A sale of business over the weekend has clearly been the cleanest solution to resolve a bank used so far.

    This is well acknowledged internationally. In fact, the Financial Stability Board has just issued a Practices paper on the Operationalisation of Transfer Tools. Also, the FDIC recently stated that it wanted to focus more on sale of business (than on using bridge bank).

    Of course, this is easier said than done.

    In the Banking Union, in order to sell a bank or create a bridge bank, one must comply with European and national rules in different Member States of the EU. We recognise that this is no small task and we are intensely collaborating with national authorities to find solutions to be able to fully operationalise these tools.

    All these efforts should not contradict the necessity to keep the other tools available, in particular the bail-in tool. It is clear indeed that for the biggest banks nobody will be ready to take them over as a whole. Bail-in stays the preferred strategy for the majority of SRB banks.

    In this regard, the Credit Suisse crisis definitely showed the need to further develop the operationalisation of the bail-in tool in a cross-border context, where loss-absorbing instruments are issued in a foreign jurisdiction and held by non-domestic investors.

    Needless to say, we have many banks under our remit that operate cross-borders. Compliance with the applicable securities laws – such as those of the US ones – can pose challenges in some cases.

    The SRB is working intensively at many levels to address this issue, from the FSB-level where a task force has been set up to the level of individual banks where IRTs are intensifying their engagement .

    But there is a lot more to crisis readiness. For my next point, I will broaden my focus to our crisis management framework. And, here, the key words are effectiveness & integration.

    4. How to make our framework more effective and integrated

    I think we can all agree that our framework should be modern, simple and streamlined. It should promote resilience and protect financial stability, but also make European banks more competitive globally.

    This is the clear first and best outcome. Unfortunately, these elements can come at a trade-off when simplification and deregulation are conflated. 

    A look across the Atlantic will remind us that the push for deregulation in 2018, which exempted US mid-sized banks from reporting the liquidity coverage ratio can be considered today as an important factor in SVB’s downfall. It incentivised the bank to take on more risks and turned out to be a blind spot for the supervisor.

    This is to say that financial stability is no free lunch and resolution will only work if our framework is credible. A 50 percent successful resolution does not exist. Either it works or it doesn’t.

    Let me be clear. Yes, our framework is complex and yes, there is room for improvement. But its simplification should not compromise our objectives.

    With this in mind, I will briefly spell out how the SRB intends to contribute to the simplification debate to become more effective.

    I will first focus on our initiatives at an SRB-level.

    The good news is that with 10 years of experience, we have found ways to deliver on our mandate in a more efficient way. In fact, we have already taken steps in that direction when we launched our strategic review in 2024, the SRM Vision 2028.

    Our core activity – resolution planning – has become more targeted and streamlined. For example, starting this year, we are no longer asking the banks to update certain deliverables like playbooks or communication plans every year. 

    Moreover, we have been collaborating closely with authorities such as the ECB and the EBA to streamline reporting, avoid duplicate requests and better coordinate our engagement.

    We also communicated a number of areas, where we consider that more simplification is possible to the Commission and EBA. One of them is the prior permissions regime – we believe authorisations could be simpler!

    But of course, there is only so much we can do within our remit. If we wish to unlock true simplification, we need to look at the wider picture.

    First, let me react to the ongoing debate on the capital framework.

    The complexity of the capital framework has drawn a lot of attention. This is understandable: banks, regulators and investors have to find their way through a complex maze of acronyms and requirements. Quite naturally, there is a temptation to tweak certain requirements or to scrape one layer.

    I share this assessment as well – we can surely have something that is as effective but simpler. All I ask however is that we review these changes to the micro- and macroprudential and resolution frameworks holistically. 

    Going concern and gone-concern requirements are two sides of the same coin. Adjusting capital or AT1 rules will directly affect the calibration of the MREL. A system-wide view should be the departing assumption!

    But let me take a step back.

    I must admit that in the current simplification debate, I am at times puzzled by the lack of ambition for a less fragmented and more integrated Banking Union. Finding pragmatic solutions to complete the Banking Union would deliver tremendous growth.

    With CMDI nearly finalised, co-legislators should now look to complete the Banking Union. The third pillar, the European Deposit Insurance Scheme, is still missing from the original design. 

    This reform would provide equal protection for all depositors across the euro area, fuelling trust in the system regardless of where a bank is located. This would help foster a more competitive environment for banks to develop cross-border activities. And we are happy to discuss the different options for building an EDIS, not exclusively the 2015 historical proposal.

    But a complete Banking Union is more than EDIS.

    With one supervisor and one resolution authority after 10 years, I do not see many reasons to continue operating with so many internal barriers. But, still, banks and authorities need to deal with many options and discretions.

    Reducing fragmentation between jurisdictions, for instance by overcoming barriers to the portability of Deposit Guarantee Scheme (DGS) funds or to group-level waivers could already be powerful measures of simplification inside the Banking Union. 

    I mentioned before that the SRM needs to stay ahead of new risks that banks may face. And here is my last keyword for today: Let’s be agile.

    5. How do we deal with new risks looming on the horizon?

    Let me start with cyber risk – perhaps this risk is already there. 

    According to the IMF, the number of cyber-attacks has more than doubled since the pandemic. Banks and their service providers are a prime target for cyber criminals and malignant foreign actors due to the high value of the data and potential for significant financial gain. 

    This was also confirmed by ENISA – the European cybersecurity agency – which found that European credit institutions were the most frequently targeted actors in the finance sector at a 46% rate.

    To be clear, these attacks do not always reach their full objective. 

    But a successful cyber-attack could easily cause significant outages, threaten the operational continuity of a bank’s critical functions and, in turn, shatter customers’ confidence in the financial system. 

    The bank would be unable to service its customers and could fail despite having ample capital and liquidity.

    At the SRB, we have already started working on how to best deal with this kind of crisis. Our starting point is that data availability will always be at the core of a successful resolution. We need to work further with banks to ensure data will always be available in case of resolution.

    To be clear with you: at this stage, I am not sure that our legal framework is entirely fit for this type of risk.

    But let’s continue the analysis before reaching a definite conclusion!

    I will now move to my final point or risk on the horizon – NBFIs.

    The wave of regulation that followed the Great Financial Crisis pushed parts of the risks outside the banking sector. Risk, by definition, did not disappear. Instead, it developed outside of the traditional banking sector, with new markets and actors, such as family offices, growing in size and relevance.

    The broad term for these actors is non-bank financial intermediaries, or NBFIs put simply. They form a tricky category, grouping together many very different market players: insurance companies, pension funds, hedge funds, family offices, etc.

    Over the last years, we have witnessed how some of these NBFIs have grown increasingly interconnected with the banking sector.

    You will surely remember the Archegos episode in 2021. 

    Credit Suisse had already been grappling with deep-seated reputational and structural problems when, in 2021, Archegos Capital Management — a US family office — defaulted on its margin calls. As one of its prime brokers, Credit Suisse suffered significant losses that exposed serious weaknesses in its risk management and control frameworks.

    Banks’ exposure to NBFIs has become an increasing concern and rightly so. This is why, authorities like the SRB need to pay a closer attention to these interconnections and monitor banks’ exposure.

    But, in my view, there is a need to go further. 

    While some of these players – namely insurers and CCPs – already have resolution planning requirements, we should start asking ourselves if the current scope of resolution is sufficient? Maybe the scope should be even broader to also encompass other NBFIs that have become systemic. When we see the speed of evolution and growth of some sectors via private Credit or stable coins, we should not wait too long to think about an appropriate toolkit for these actors (when systemic and in failure).

    These are clearly questions that will need to be addressed at FSB-level. 

    Let me conclude.

    6. Conclusion

    I remember that, when negotiating the key attributes of the FSB around 2010 – 2013, the table was divided between “prophets” describing a brave new world to come, where financial stability would be guaranteed forever thanks to resolution, and, in contrast, “disbelievers” who were much more sceptical and thinking that at the end governments will still be obliged to step in.

    Today, we can safely say that the reality is in between: on the one hand, we have taken decisive steps to ensure our citizens that, all other things equal, they won’t pay more taxes in case of an idiosyncratic failure of a banking group. And I can tell you that the SRB/SRM is working day after day to achieve this goal. 

    However, on the other hand, let’s also recognise that our financial world is evolving rapidly, perhaps even more rapidly than before. That implies that we should stay humble and sufficiently agile to address the new challenges to come at the service of financial stability, here in Europe, and beyond.

    Thank you for your attention.

    Continue Reading

  • Low NAPR as a Novel Indicator for Predicting Escherichia coli Bloodstr

    Low NAPR as a Novel Indicator for Predicting Escherichia coli Bloodstr

    Introduction

    Bloodstream infections (BSIs) are a major global health problem in the elderly as age-related immune defects, multiple comorbid conditions and diminished physiological reserves predispose these patients to high morbidity, prolonged hospitalization and increased mortality.1,2 Although Escherichia coli (E.coli) is the predominant pathogen causing BSIs, non-E.coli organisms such as Pseudomonas aeruginosa and Klebsiella pneumoniae associated with BSIs are known to be more severe, and result in higher mortality and complex treatment requirements necessitating a longer hospital stay.3 The elderly are at particular risk for complicated clinical courses due to late diagnosis which may limit prompt initiation of appropriate treatment, thereby emphasizing the need for pathogen-specific risk stratification approach.

    Neutrophil-to-platelet ratio (NPAR) also reflects both systemic inflammation and thrombotic risk.4 Elevated NPAR is associated with poor prognosis in sepsis and other bacterial infections, but the role of NPAR in predicting E.coli bloodstream infection (BSI) among elderly patients was not well studied.5 With development of microfluidics and novel phage-based detection systems, combining NPAR with pathogen specific diagnostic tools holds promise in the early management of E.coli BSI. Though evidence suggests that patients experience higher mortality in non-E.coli compared to E.coli infection causing BSIs, there is currently no study that has directly compared risk of mortality between E.coli and non- E.coli BSIs among elderly population. Furthermore, the utility of NPAR in predicting E.coli BSI among elderly patients remains unexplored.

    This study aimed to compare mortality between E.coli versus non-E.coli BSIs among elderly inpatients, explore potential utility of NPAR as a diagnostic biomarker to predict E.coli BSI and its prognostic implications among them.

    Methods

    Study Design and Participants

    This single-center, retrospective cohort study encompassed 527 elderly patients diagnosed with BSIs between December 2011 and February 2024 at the Second Medical Center of the Chinese PLA General Hospital through the hospital’s infection information system. The inclusion criteria were: (1) age greater than 65 years; and (2) availability of complete medical records. The exclusion criteria were as follows: (1) Incomplete medical records. The study protocol was reviewed and approved by the Chinese PLA Hospital Ethical Committee (Approval No.NO. S2024-359-02) and complied with the Declaration of Helsinki. Due to the retrospective design, informed consent was waived.

    Data Collection

    Data on NPAR levels and other covariates, including demographic and clinical factors, were collected at baseline. NPAR was measured as both a continuous variable and categorized into tertiles (T1, T2, and T3). The outcome of interest was the occurrence of E.coli BSI, which was confirmed by blood culture. A BACT/ALERT 3D automatic blood culture instrument (bioMérieux, France) was used for blood culture, a Vitek2 Compact automatic microbiological identification and antimicrobial susceptibility analysis system (bioMérieux, France) was used for strain identification and antimicrobial susceptibility testing. Baseline data were collected on a range of demographic and clinical characteristics, including age, gender, department, smoking status, comorbidities (eg, diabetes mellitus, hypertension, coronary disease), and clinical interventions (eg, number of operations, use of ventilator, central venous catheter, urinary catheter, chemotherapy, radiotherapy, blood transfusion, polypharmacy regimens). The hospitalization duration was also recorded as a continuous variable.

    Statistical Analysis

    Descriptive statistics were used to summarize the baseline characteristics of the participants. Continuous variables were expressed as means with standard deviations, and categorical variables were reported as frequencies and percentages. Categorical variables were compared using the chi-square or Fisher’s exact test; continuous variables were analyzed using the Student’s t-test, Mann–Whitney U-test or Kruskal–Wallis test as appropriate; logistic regression was used to assess the predictive value of NPAR for E. coli BSI; Cox proportional hazards models were applied for survival analysis; and the Kaplan–Meier method with Log rank test was used to compare mortality between groups. To evaluate the association between NPAR and E. coli BSI, we constructed three models in our analysis: Model 1: Unadjusted crude model. Model 2: Adjusted for age and sex. Model 3: Based on Model 2, we further adjusted for variables that showed statistical significance in the univariate analysis, as well as through reverse adjustment, including department, coronary disease, and combination of drug. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for both continuous NPAR and NPAR tertiles (T1 as the reference group). The dose-response relationship for continuous NPAR was assessed, and the trend across NPAR tertiles was evaluated using a likelihood ratio test. The non-linearity of the dose-response relationship was examined using a non-linear regression model. The p-value for trend was calculated to assess the monotonicity of the dose-response across tertiles of NPAR. Statistical significance was set at P < 0.05 for all analyses. All statistical analyses were performed using R (version 3.6.3) statistical software.

    Results

    Baseline Characteristics

    A cohort of 510 elderly participants (mean age 89.9 ± 8.5 years) meeting inclusion and exclusion criteria was stratified into E.coli BSI (n=92, 18.2%) and non-E.coli BSIs groups (n=418, 81.8%) based on the causative agent of bloodstream infection. The baseline characteristics of the overall cohort and the two groups are summarized in Table 1. No intergroup differences in age (P=0.978), gender (P=0.229), smoking status (P=0.193), diabetes (P=0.614), or hypertension (P=1.0). Higher coronary disease prevalence in non-E.coli group (57.2% vs 32.3%, P<0.001) and comparable surgical frequency (P=0.441).

    Table 1 Baseline Clinical Characteristic of Enrolled Bloodstream Infection Patients

    Clinical Interventions and Outcomes

    As shown in Table 2, 49.1% (n = 510) patients did not require ventilator support, with a higher proportion of patients in the E. coli group (61.3%) compared to the non-E.coli group (46.4%) (P = 0.045). Similarly, the duration of central venous catheter use was significantly longer in the E.coli group, with 25.8% of patients requiring it for more than 90 days, compared to 14.1% in the non-E.coli group (P = 0.023). Blood transfusion was more frequently administered in the E.coli group (73.1% vs 58.1%, P = 0.01). The length of hospital stay did not differ significantly between the two groups (P = 0.563), with a median length of stay of 90.0 days (IQR: 65.4, 96.0) in the overall cohort.

    Table 2 Clinical Interventions and Outcomes of Enrolled Bloodstream Infection Patients

    Departments and Infection Source Distribution

    There was a statistically significant difference between E.coli group and non-E.coli groups regarding the departments in which patients were hospitalized (P = 0.046) (Table 1). The distribution of departments of patients with E.coli bloodstream infections were as follows: Cardiology (16.30%), Endocrinology (3.26%), Gastroenterology (35.87%), Hematology (1.09%), ICU (4.35%), Nephrology (4.35%), Neurology (5.43%), Oncology (2.17%), and Respiratory Medicine (10.87%) (Figure 1). The distribution of infection sources among patients with E.coli bloodstream infections were as follows: Biliary infection source (28.26%), non-biliary intra-abdominal infection (3.26%), Pulmonary infection source (16.30%), Unidentified infection source (23.92%), and Urinary tract infection source (28.26%) (Figure 1). Also, we found that non-E. coli pathogens were the primary contributors. Among these, Staphylococcus species were the most prevalent, accounting for 125 isolates out of 510 total samples (Supplementary Table 1).

    Figure 1 Distribution of infection sources and departments in patients with Escherichia coli bloodstream infections. (A) Distribution of infection sources in patients with Escherichia coli bloodstream infections. (B) Distribution of infection sources in internal medicine bloodstream Infection patients with Escherichia coli. (C) Distribution of infection sources in surgeon bloodstream infection patients with Escherichia coli. (D) Distribution of departments of patients with Escherichia coli bloodstream infections.

    NPAR Associations with E.coli BSI

    The association between NPAR and E.coli BSI was evaluated using three models (Table 3). All models demonstrated a statistically significant inverse relationship between continuous NPAR and E.coli BSI risk: Model 1, OR=0.88 (95% CI: 0.84, 0.93; P < 0.001), Model 2, OR =0.88 (95% CI: 0.84, 0.92; P < 0.001), and in Model 3, OR=0.89 (95% CI: 0.84, 0.94; P < 0.001). Using Tertile 1 (T1) as the reference group, in Tertile 2 (T2), the odds of infection were significantly reduced, with Model 1(OR=0.53; 95% CI: 0.32, 0.89; P = 0.017), Model 2(OR= 0.50; 95% CI: 0.29, 0.84; P = 0.01) and Model 3(OR =0.46; 95% CI: 0.26, 0.81; P = 0.008). In Tertile 3 (T3), the odds of infection were even more substantially reduced, with Model 1(OR =0.21; 95% CI: 0.11, 0.40; P < 0.001), Model 2 (OR=0.21; 95% CI: 0.11, 0.39; P < 0.001), and Model 3 (OR= 0.23; 95% CI: 0.11, 0.46; P < 0.001). Furthermore, a statistically significant trend towards decreasing odds of infection across increasing tertiles of NPAR was observed in all models (P for trend < 0.001). These findings suggest that higher NPAR levels correlate with a reduced likelihood of E.coli BSI, with the risk decreasing progressively across tertiles. This aligns with NPAR’s role as a composite inflammatory marker, where elevated values may reflect an attenuated susceptibility to systemic infection.

    Table 3 Associations of NPAR with Escherichia coli Bloodstream Infections in Elder Patients

    Dose-Response Relationship Between NPAR and E.coli BSI

    A linear relationship between NPAR and E.coli BSI was statistically significant (P < 0.05), while a non-linear relationship was not evident (P = 0.424, Cutoff value =19.4) (Figure 2). Therefore, as NPAR increases, there is a linear decrease in E.coli BSI risk. Hence NPAR may serve as a continuous protective marker rather than having a threshold at a particular level.

    Figure 2 The dose-response relationship between NPAR and Escherichia coli bloodstream infection. (NAPR: neutrophil-to-platelet ratio).

    Survival Analysis

    The Kaplan-Meier survival plots of patients with E.coli and non-E.coli BSIs are shown in Figure 3, which revealed higher survival probability of patients with E coli compared with non-E coli counterparts (HR=0.43; 95% CI 0.21, 0.88, P=0.021). Notably, the survival probability for patients with non-E.coli infections dropped more rapidly over time, whereas the E.coli group exhibited a more gradual decline in survival.

    Figure 3 Kaplan-Meier curve analysis of patients in Escherichia coli and non-Escherichia coli bloodstream infection groups.

    Antimicrobial Resistance Pattern

    As shown in Table 4 and Figure 4, almost 97.1% of E.coli isolates were resistant to Ampicillin (AMP), 77.1% were resistant to Ciprofloxacin (CIP), 74.3% were resistant to Cefazolin (CEZ), 72.9% were resistant to Levofloxacin (LVX), and 72.7% were resistant to Ampicillin/Sulbactam (AMP/SUL). Overall, E.coli isolates exhibited no resistance to the following antibiotics: Amikacin (AMK), Ertapenem (ETP), Tigecycline (TGC), and Cefotetan (CET). The antibiotic with the highest resistance rate in E.coli isolates from bloodstream infection patients in the respiratory department were AMP (100%), Ceftriaxone (CTX, 100%), CEZ (100%). AMP (100%), Doxycycline (DXY, 100%), Gentamicin (GEN, 100%). In contrast, the general surgery department had a lower resistance rate for antibiotics like Ampicillin/Sulbactam (60.0%) and Gentamicin (66.7%). Notably, antibiotics like Amikacin, Ertapenem, and Tigecycline showed a resistance rate of 0% across all departments. Resistance to Cefotetan was absent across all departments tested.

    Table 4 Antibiotic Resistance Rate of Escherichia coli in Bloodstream Infection Patients

    Figure 4 Overall antibiotic resistance rate of Escherichia coli.

    Discussion

    Our study provides several important implications to be addressed clinically for BSIs in extremely elderly patients. First, we demonstrated that non-E. coli BSIs had a significantly higher risk of mortality compared to E. coli BSI in extremely elderly inpatients with the mean age of 89.9 ± 8.5 years, indicating the clinical importance of identifying the pathogen causing infection. We also provided that low NPAR was inversely associated with the presence of E. coli BSI which may be useful early identification and risk stratification in elderly, leading to a more tailored and early intervention to be initiated.

    Among 30,923 cases of E.coli bloodstream infections, 2961 cases of 30-day mortality were observed, resulting in an overall 30-day mortality of 9.6% (2961/30,923).6 Hospital-acquired or third-generation-cephalosporin-resistant E.coli BSI showed significantly higher mortality rates compared to community-acquired or third-generation-cephalosporin-susceptible E.coli BSI.6 In our cohort of elderly patients, non-E.coli BSIs were associated with higher mortality compared to E.coli BSIs, even after adjustment for demographics and clinical factors, which is consistent with previous studies. Various studies have reported that the reasons why high mortality is associated with non-E.coli infections include difficulty in diagnosis, limited treatment options, and increased infection severity due to multidrug-resistant organisms or high virulence.6,7 As elderly patients have weak immunity and often suffer from multiple underlying diseases, there would be a greater concern about their course and response to treatment.8,9 Our findings indicate that it is vital to early detection and proper management for non-E.coli BSIs. Previous studies have reported that E.coli BSI in elderly patients predominantly originate from urinary tract infections,10 which is consistent with the findings of our study, where urinary and biliary tract infections were identified as the leading sources. These infections typically elicit a relatively mild systemic inflammatory response, characterized by only a modest elevation in neutrophil counts and minimal alterations in platelet levels. In contrast, non-E. coli BSIs – such as those caused by Staphylococcus aureus, Klebsiella pneumoniae, or Enterococcus faecalis – are more often associated with catheter-related infections, non-biliary intra-abdominal infections, and respiratory tract infections, which usually trigger a more severe systemic inflammatory response.11 It is reported that thrombocytopenia was independently associated with mortality among patients with BSIs.12 This aligns with prior studies showing NPAR and related indices (eg, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio) as strong, independent predictors of sepsis severity and mortality.13 A high NPAR captures a dual-risk profile: amplified inflammatory response and impaired hemostatic balance, both of which have been independently linked to increased mortality in bloodstream infections.14 In our multivariable Cox regression models, high NPAR remained significantly associated with mortality even after adjusting for age, comorbidities, and infection source, indicating its robust prognostic value. Clinically, low NPAR may serve as an early indicator of E. coli BSI and help clinicians stratify patients who are likely to have more benign infection courses, potentially guiding early empirical therapy decisions and resource allocation. Conversely, persistently elevated NPAR should prompt vigilance for non-E. coli pathogens or complicated infection sources.

    The prevalence of E.coli producing extended-spectrum beta-lactamases (ESBL) among BSI patients was 40.98%. E.coli isolates were generally sensitive to carbapenems and β-lactam/β-lactamase inhibitor combinations. Hospital-acquired infections, biliary tract infections, gastric tube insertion procedures, and prior cephalosporin administration were identified as independent risk factors for the isolation of ESBL-producing strains. ESBL positivity, hospital-acquired infections, and cancer were independent risk factors for mortality.15 Meta-analysis results indicate that it is necessary to shift current treatment practices from antibiotic escalation strategies that delay appropriate therapy to early, relatively aggressive, and comprehensive antibiotic treatment, especially in patients with BSIs caused by Klebsiella pneumoniae or E.coli.16 Choi et al found that E.coli is the most common pathogenic microorganism in BSIs, accounting for 32.3%, and the adjusted hazard ratio (aHR) for 30-day mortality and subsequent medical costs for E.coli BSI was lower compared to other microorganisms causing BSI. E.coli-BSI resulted in lower mortality rates during the first 7 days and from days 8 to 30 compared to BSIs caused by other microorganisms.17 Our study found that the proportion of internal medicine patients was higher in the non-E.coli group, while E.coli infections were more common in the surgical department. The incidence of coronary artery disease was lower in the E.coli group, whereas it was higher in the non-E.coli group. There were significant differences in the duration of ventilator use and central venous catheter use between the E.coli and non-E.coli groups, with patients in the non-E.coli group having a longer durations of use.

    NPAR is a simple, readily accessible measure derived from routine blood tests, and it has been proposed as a marker for various infectious and inflammatory conditions.18–20 As shown in Figure 2, the OR for E.coli BSI decreases with increasing NPAR values. The analysis indicates a significant overall association between NPAR and the risk of E.coli bloodstream infection. Overall P-value: <0.001, indicating a strong statistical significance for the association between NPAR and the risk of E.coli bloodstream infection. In our analysis, the non-linear regression yielded a p-value of 0.424, indicating no significant evidence of a non-linear relationship between NPAR and infection risk. Therefore, we conclude that the relationship is best modeled as linear, suggesting a consistent, proportional association between NPAR and infection risk. OR (95% CI): The odds ratio decreases progressively with higher NPAR levels, approaching 1, indicating that higher NPAR values are associated with a reduced risk of E.coli bloodstream infection. Our findings suggest that low NPAR values are strongly associated with an increased risk of E.coli infection, with patients in the lowest NPAR tertile having substantially higher odds of having an E.coli infection compared to those in the highest tertile. This association remained consistent across various analytical models, further reinforcing the evidence for NPAR as a predictor of E.coli infections. Although the precise mechanisms linking NPAR to infection risk are not fully understood, it is believed that NPAR reflects the balance between inflammatory and immune responses.21–23 During E. coli BSI, lipopolysaccharides (LPS) derived from the bacterial cell wall activate macrophages and other immune cells via Toll-like receptor 4 (TLR4) and related signaling pathways.24 This activation triggers a cascade release of proinflammatory cytokines, including interleukin (IL)-6, IL-1, and TNF-α. Among these, IL-6 plays a central role in the IL-6–liver axis by markedly stimulating hepatic synthesis of thrombopoietin (TPO), the key regulator of megakaryocyte proliferation and differentiation.25 Elevated TPO levels subsequently enhance platelet production, resulting in reactive thrombocytosis.25 In addition, several inflammatory cytokines, such as IL-6, IL-11, and granulocyte-macrophage colony-stimulating factor (GM-CSF), may directly or indirectly act on hematopoietic stem and progenitor cells to promote megakaryocyte maturation and platelet release. In contrast, non-E. coli BSIs like S. aureus can induce platelet aggregation and clearance through α-toxin- and ClfA-mediated mechanisms, thereby promoting thrombocytopenia and contributing to an elevated NPAR.26 Together, these inflammatory responses provide a plausible explanation for the increased platelet counts frequently observed in E. coli BSI and may partially underlie the association between a low NPAR and disease progression.

    The antibiotic resistance profiles of E.coli isolates in this study reveal significant variability across different clinical departments. High resistance rates to Ampicillin, Ampicillin/Sulbactam, and Cefazolin are consistent with previous reports of widespread beta-lactam resistance.27,28 However, the absence of resistance to Amikacin and Ertapenem is encouraging, as these antibiotics are vital for treating multidrug-resistant infections. The elevated resistance rates to Ciprofloxacin and Levofloxacin in the respiratory and cardiology departments may be linked to the frequent use of these antibiotics in those specialties. The lack of resistance to Tigecycline and Ertapenem across all departments suggests that these antibiotics could serve as effective treatment options for E.coli bloodstream infections. The relatively low resistance rates to Imipenem/Cilastatin and Meropenem in most departments further highlight the importance of carbapenems in managing severe E.coli infections. The significant resistance to Ticarcillin/Clavulanate, particularly in the general surgery department, underscores the need for more judicious use of this antibiotic to prevent the development of further resistance. Doctors should emphasize careful monitoring of antibiotic use, restricting the use of broad-spectrum antibiotics, and promoting individualized treatment guided by sensitivity testing to reduce the spread of resistance.29,30

    Conclusion

    The NPAR, as demonstrated in our study, holds significant potential as a simple, cost-effective, and globally applicable biomarker for early identifying and targeted managing E. coli BSI in elderly patients. Low NPAR is associated with an increased likelihood of E. coli BSI and can help clinicians identify high-risk patients who may benefit from early therapeutic interventions. In future research, the role of NPAR as a predictive and prognostic biomarker for E.coli BSI could be further extended to populations across different age groups, with subsequent studies needed to explore longitudinal NPAR trends during treatment as a monitoring biomarker, and further elucidate the underlying biological mechanisms linking NPAR with infection susceptibility and clinical outcomes in E. coli BSI.

    Data Confidentiality Statement

    All patient data were handled in strict compliance with confidentiality regulations. The data were anonymized prior to analysis, and no identifiable personal information was disclosed or shared outside the research team.

    Data Sharing Statement

    The data are available from the corresponding author on reasonable request.

    Consent to Participate

    This research was approved and waived the consent by the Ethics Committee of Chinese PLA General Hospital (NO. S2020-25601). Informed consent was not required due to the retrospective nature of the study design. All authors confirm this study adheres to the Declaration of Helsinki.

    Author Contributions

    All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

    Funding

    This retrospective study was supported by National Clinical Research Center for Geriatric Diseases Open Project: NCRCG-PLAGH-2022012 and NCRCG-PLAGH-2023004; Beijing Natural Science Foundation: L222014.

    Disclosure

    All authors in this study declare no competing conflicts.

    References

    1. Leibovici-Weissman Y, Tau N, Yahav D. Bloodstream infections in the elderly: what is the real goal? Aging Clin Exp Res. 2021;33(4):1101–1112. PMID: 31486996. doi:10.1007/s40520-019-01337-w

    2. Lin H, Gao Y, Qiu Y, et al. The prognostic factors of bloodstream infection in immunosuppressed elderly patients: a retrospective, single-center, five-year cohort study. Clin Interv Aging. 2022;17:1647–1656. PMID: 36425478; PMCID: PMC9680683. doi:10.2147/CIA.S386922

    3. Mondal U, Warren E, Bookstaver PB, et al. Incidence and predictors of complications in Gram-negative bloodstream infection. Infection. 2024;52(5):1725–1731. PMID: 38436912; PMCID: PMC11499525. doi:10.1007/s15010-024-02202-3

    4. Gong Y, Li D, Cheng B, et al. Increased neutrophil percentage-to-albumin ratio is associated with all-cause mortality in patients with severe sepsis or septic shock. Epidemiol Infect. 2020;148:e87. PMID: 32238212; PMCID: PMC7189348. doi:10.1017/S0950268820000771

    5. Mousa N, Salah M, Elbaz S, et al. Neutrophil percentage-to-albumin ratio is a new diagnostic marker for spontaneous bacterial peritonitis: a prospective multicenter study. Gut Pathog. 2024;16(1):18. PMID: 38561807; PMCID: PMC10985869. doi:10.1186/s13099-024-00610-2

    6. MacKinnon MC, McEwen SA, Pearl DL, et al. Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study. BMC Infect Dis. 2021;21(1):606. PMID: 34172003; PMCID: PMC8229717. doi:10.1186/s12879-021-06326-x

    7. Leistner R, Gürntke S, Sakellariou C, et al. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort. Infection. 2014;42(6):991–997. PMID: 25100555. doi:10.1007/s15010-014-0670-9

    8. Chen Q, Ma G, Cao H, et al. Risk factors and diagnostic markers for Escherichia coli bloodstream infection in older patients. Arch Gerontol Geriatr. 2021;93:104315. PMID: 33310397. doi:10.1016/j.archger.2020.104315

    9. Giannella M, Pascale R, Toschi A, et al. Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study. Clin Microbiol Infect. 2018;24(10):1077–1083. PMID: 29371138. doi:10.1016/j.cmi.2018.01.013

    10. Choi HJ, Jeong SH, Shin KS, et al. Characteristics of Escherichia coli urine isolates and risk factors for secondary bloodstream infections in patients with urinary tract infections. Microbiol Spectr. 2022;10(4):e0166022. PMID: 35862950; PMCID: PMC9430824. doi:10.1128/spectrum.01660-22

    11. Timsit JF, Ruppé E, Barbier F, et al. Bloodstream infections in critically ill patients: an expert statement. Intensive Care Med. 2020;46(2):266–284. PMID: 32047941; PMCID: PMC7223992. doi:10.1007/s00134-020-05950-6

    12. Adelman MW, Casarin S, Kurian J, et al. Platelets and mortality in bloodstream infection: a multicenter cohort study. Clin Microbiol Infect. 2025;31(10):1733–1736. PMID: 40744277; PMCID: PMC12377423. doi:10.1016/j.cmi.2025.07.021

    13. Gao L, Shi Q, Li H, et al. Prognostic value of the combined variability of mean platelet volume and neutrophil percentage for short-term clinical outcomes of sepsis patients. Postgrad Med. 2021;133(6):604–612. PMID: 32912023. doi:10.1080/00325481.2020.1823137

    14. Cecconi M, Evans L, Levy M, et al. Sepsis and septic shock. Lancet. 2018;392(10141):75–87. PMID: 29937192. doi:10.1016/S0140-6736(18)30696-2

    15. Zhao S, Wu Y, Dai Z, et al. Risk factors for antibiotic resistance and mortality in patients with bloodstream infection of Escherichia coli. Eur J Clin Microbiol Infect Dis. 2022;41(5):713–721. doi:10.1007/s10096-022-04423-6

    16. Lodise TP, Zhao Q, Fahrbach K, et al. A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long? BMC Infect Dis. 2018;18(1):625. doi:10.1186/s12879-018-3524-8

    17. Choi MH, Kim D, Kim J, et al. Shift in risk factors for mortality by period of the bloodstream infection timeline. J Microbiol Immunol Infect. 2024;57(1):97–106. doi:10.1016/j.jmii.2023.11.008

    18. Lan CC, Su WL, Yang MC, et al. Predictive role of neutrophil-percentage-to-albumin, neutrophil-to-lymphocyte and eosinophil-to-lymphocyte ratios for mortality in patients with COPD: evidence from NHANES 2011–2018. Respirology. 2023;28(12):1136–1146. doi:10.1111/resp.14589

    19. Ji W, Li H, Qi Y, et al. Association between neutrophil-percentage-to-albumin ratio (NPAR) and metabolic syndrome risk: insights from a large US population-based study. Sci Rep. 2024;14(1):26646. PMID: 39496695; PMCID: PMC11535182. doi:10.1038/s41598-024-77802-y

    20. Dong K, Zheng Y, Wang Y, et al. Predictive role of neutrophil percentage-to-albumin ratio, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index for mortality in patients with MASLD. Sci Rep. 2024;14(1):30403. PMID: 39638820; PMCID: PMC11621551. doi:10.1038/s41598-024-80801-8

    21. Ding W, La R, Wang S, et al. Associations between neutrophil percentage to albumin ratio and rheumatoid arthritis versus osteoarthritis: a comprehensive analysis utilizing the NHANES database. Front Immunol. 2025;16:1436311. PMID: 39917306; PMCID: PMC11799277. doi:10.3389/fimmu.2025.1436311

    22. Yang F, Dong R, Wang Y, et al. Prediction of pulmonary infection in patients with severe myelitis by NPAR combined with spinal cord lesion segments. Front Neurol. 2024;15:1364108. PMID: 38481940; PMCID: PMC10932995. doi:10.3389/fneur.2024.1364108

    23. Zawiah M, Khan AH, Abu Farha R, et al. Predictors of stroke-associated pneumonia and the predictive value of neutrophil percentage-to-albumin ratio. Postgrad Med. 2023;135(7):681–689. PMID: 37756038. doi:10.1080/00325481.2023.2261354

    24. Luo R, Yao Y, Chen Z, et al. An examination of the LPS-TLR4 immune response through the analysis of molecular structures and protein-protein interactions. Cell Commun Signal. 2025;23(1):142. PMID: 40102851; PMCID: PMC11921546. doi:10.1186/s12964-025-02149-4

    25. Tsutsumi N, Masoumi Z, James SC, et al. Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis. Cell. 2023;186(19):4189–4203.e22. PMID: 37633268; PMCID: PMC10528194. doi:10.1016/j.cell.2023.07.037

    26. Xia Y, Sun C, Zhou K, et al. Platelet glycoprotein Ibα cytoplasmic tail exacerbates thrombosis during bacterial sepsis. Int J Mol Sci. 2024;25(21):11548. PMID: 39519103; PMCID: PMC11546206. doi:10.3390/ijms252111548

    27. Nasrollahian S, Graham JP, Halaji M. A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli. Front Cell Infect Microbiol. 2024;14:1387497. PMID: 38638826; PMCID: PMC11024256. doi:10.3389/fcimb.2024.1387497

    28. Sundaramoorthy NS, Shankaran P, Gopalan V, et al. New tools to mitigate drug resistance in Enterobacteriaceae – escherichia coli and Klebsiella pneumoniae. Crit Rev Microbiol. 2023;49(4):435–454. PMID: 35649163. doi:10.1080/1040841X.2022.2080525

    29. Katip W, Rayanakorn A, Oberdorfer P, et al. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: a propensity score matching study. J Infect Public Health. 2023;16(8):1249–1255. PMID: 37295057. doi:10.1016/j.jiph.2023.05.024

    30. Katip W, Rayanakorn A, Sornsuvit C, et al. High-loading-dose colistin with nebulized administration for carbapenem-resistant acinetobacter baumannii pneumonia in critically ill patients: a retrospective cohort study. Antibiotics. 2024;13(3):287. PMID: 38534721; PMCID: PMC10967279. doi:10.3390/antibiotics13030287

    Continue Reading

  • Somnigroup Proposes to Acquire Leggett & Platt in All-Stock Transaction

    • Proposal represents 30.3% premium to the average closing price of Leggett & Platt’s shares during the last 30 trading days
    • Combination would provide Leggett & Platt shareholders with significant premium and opportunity to participate in combined company growth

    DALLAS, Dec. 1, 2025 /PRNewswire/ — Somnigroup International Inc. (NYSE: SGI, “Company” or “Somnigroup”) today announced that it submitted a proposal to the Board of Directors of Leggett & Platt Inc. (NYSE: LEG) to acquire all outstanding common shares of Leggett & Platt in an all-stock transaction (the “Proposal”). Under the terms of the Proposal, Leggett & Platt shareholders would receive shares of Somnigroup common stock with a market value of $12.00 for every one share of Leggett & Platt common stock, based on a fixed exchange ratio to be agreed. The Proposal offers Leggett & Platt shareholders a 30.3% premium to the average closing price of Leggett & Platt’s shares during the last 30 trading days, representing a value not achieved by LEG shares since December 2024.

    The all-stock structure would enable Leggett & Platt shareholders to participate in the future growth potential of the combined company on a tax-deferred basis.

    “Leggett & Platt has been an important supplier to our Company for many years,” said Scott Thompson, Chairman and CEO of Somnigroup. “This proposal would deliver significant value to Leggett & Platt shareholders through a compelling premium and tax-advantaged participation in our combined platform, while also being accretive before synergies to all Somnigroup shareholders.”

    The Proposal was delivered to the Leggett & Platt Board in a letter on December 1, 2025. The full text of the letter is included below:

    ###

    December 1, 2025

    Board of Directors
    Leggett & Platt Incorporated
    1 Leggett Road
    Carthage, Missouri 64836

    Attention:  Mr. Karl G. Glassman, Board Chairman, President and Chief Executive Officer

    Dear Karl and Members of the Board:

    I am writing to express our strong interest in pursuing a business combination transaction between Somnigroup International Inc. (“Somnigroup”) and Leggett & Platt Incorporated (“Leggett & Platt”).

    We propose that Somnigroup acquire all of the outstanding shares of Leggett & Platt in an all-stock merger with a wholly owned subsidiary of Somnigroup, in which each outstanding share of Leggett & Platt common stock would be exchanged for shares of Somnigroup common stock having a market value of $12.00, based on a fixed exchange ratio to be agreed. 

    Our proposed merger consideration represents a premium of approximately 17.0% to the closing price of Leggett & Platt shares on November 28, 2025, and a premium of approximately 30.3% over the average closing price of Leggett & Platt shares during the last 30 trading days – a value that Leggett & Platt shareholders have not seen since December 2024.

    In addition, by receiving consideration comprised entirely of Somnigroup common stock, your shareholders will have the opportunity to participate fully on a tax-deferred basis in the significant growth potential and synergies of the combined company.

    We believe that a combination of Leggett & Platt with Somnigroup would be uniquely compelling for both companies and all of our collective stakeholders. Joining Leggett & Platt with a leading bedding manufacturer and bedding retailer would unquestionably foster significant strategic advantages and efficiencies for the combined company.  Also, as you know, Somnigroup and Leggett & Platt have enjoyed an excellent commercial arrangement for many years.  A significant mutual benefit of our proposal would be to ensure that this arrangement will continue without interruption.

    Leggett & Platt would continue to operate independently under the Somnigroup umbrella.  Like Mattress Firm, Tempur Sealy and Dreams, Leggett & Platt’s leadership team would enjoy significant autonomy.  Leggett & Platt would also benefit from having a substantial and reliable customer in Tempur Sealy and greater opportunities for growth and success, all with a lower cost of capital and the strategic backing of Somnigroup. 

    Additionally, because Leggett & Platt’s business is complementary to Somnigroup’s businesses, we would expect to not only retain most of Leggett & Platt’s management team and employees, whose knowledge, experience and talent would be invaluable to the Somnigroup organization, but also provide them future career opportunities in the broader Somnigroup organization. We also expect to retain a significant presence in Carthage.

    We contemplate that our transaction would be subject only to customary closing conditions, including the receipt of necessary regulatory approvals, which we expect would be obtained without difficulty or delay.  Our transaction would not be subject to any financing contingency or require approval by Somnigroup’s shareholders.

    Our proposal has been unanimously authorized by our Board of Directors.  Based on our long history with Leggett & Platt, we would expect to be able to promptly complete confirmatory due diligence and execute definitive agreements.  

    Our financial advisors are Goldman Sachs & Co. LLC and our legal advisors are Cleary Gottlieb Steen & Hamilton LLP.

    This proposal is subject to satisfactory completion of due diligence, the negotiation and execution of definitive transaction documents, and approval by the boards of directors of both companies. Unless and until such time, no obligation, commitment or undertaking of any kind shall arise as a result of this letter or any subsequent discussions.

    We believe this is a unique opportunity to deliver significant value to Leggett & Platt shareholders and better position a combined company to drive future shareholder value. We seek to work with you on a friendly basis to complete this transaction successfully and expeditiously.

    We hope that you share our enthusiasm and we would appreciate a response by December 22, 2025.

    Sincerely,

    Scott L. Thompson
    President, Chief Executive Officer and Chairman of the Board

    ###

    Customary Approvals 
    Completion of the contemplated transaction is contingent upon reaching a definitive agreement and would be subject to the satisfaction of customary closing conditions, including receipt of Leggett & Platt shareholder approval and required regulatory approvals. The proposed transaction would not be subject to any financing contingencies or approval by Somnigroup’s shareholders.

    Forward Looking Statements
    This communication contains statements that may be characterized as “forward-looking,” within the meaning of the federal securities laws. Such statements might include information concerning one or more of the Company’s plans, guidance, objectives, goals, strategies and other information that is not historical information. When used in this release, the words “assumes,” “estimates,” “expects,” “guidance,” “anticipates,” “might,” “projects,” “plans,” “proposed,” “targets,” “intends,” “believes,” “will,” “contemplates” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding Somnigroup’s proposal to acquire Leggett & Platt (including the benefits, results, effects and timing of a transaction) and any statements regarding Somnigroup’s (and Somnigroup’s and Leggett & Platt’s combined) expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities and plans and objectives of management. Any forward-looking statements contained herein are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company (or the combined company) will realize these expectations, meet its guidance or that these beliefs will prove correct.

    Numerous factors, many of which are beyond the Company’s control, could cause actual results to differ materially from any that may be expressed herein as forward-looking statements. These potential risks include general economic, financial and industry conditions, particularly conditions relating to the financial performance and related credit issues present in the retail sector, as well as consumer confidence and the availability of consumer financing; the impact of the macroeconomic environment in both the U.S. and internationally on the Company; uncertainties arising from national and global events; industry competition; the effects of consolidation of retailers on revenues and costs; and consumer acceptance and changes in demand for the Company’s products and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. There may be other factors that may cause the Company’s actual results to differ materially from the forward-looking statements. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

    Additional Information
    This communication relates to a proposal which Somnigroup has made for a business combination transaction with Leggett & Platt. In furtherance of this proposal and subject to future developments, Somnigroup (and, if a negotiated transaction is agreed, Leggett & Platt) may file one or more registration statements, proxy statements, tender offer statements, prospectuses or other documents with the Securities and Exchange Commission (the “SEC”). This communication is not a substitute for any proxy statement, registration statement, tender offer statement, prospectus or other document Somnigroup and/or Leggett & Platt may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF SOMNIGROUP AND LEGGETT & PLATT ARE URGED TO READ THE PROXY STATEMENT(S), REGISTRATION STATEMENT(S), TENDER OFFER STATEMENT(S), PROSPECTUS(ES) AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any definitive proxy statement(s) or prospectus(es) (if and when available) will be mailed to stockholders of Somnigroup and Leggett & Platt, as applicable. Investors and security holders will be able to obtain copies of these documents (if and when available) as well as other filings containing information about Somnigroup and Leggett & Platt, free of charge on the SEC’s website at www.sec.gov. Those documents, when filed, as well as Somnigroup’s other public filings with the SEC, may be obtained free of charge on Somnigroup’s website at www.somnigroup.com.

    Somnigroup and its directors, executive officers and certain other members of management and employees may be deemed to be participants in any solicitation with respect to the proposed transaction under the rules of the SEC. You can find information about Somnigroup’s executive officers and directors in Somnigroup’s definitive proxy statement filed with the SEC on March 31, 2025. Additional information regarding the interests of such potential participants will be included in one or more registration statements, proxy statements, tender offer statements, prospectuses or other documents filed with the SEC if and when they become available. You may obtain free copies of these documents using the sources indicated above.

    This communication shall not constitute an offer to sell, buy or exchange or the solicitation of an offer to sell, buy or exchange any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

    About Somnigroup 
    Somnigroup (NYSE: SGI) is the world’s largest bedding company, dedicated to improving people’s lives through better sleep. With superior capabilities in design, manufacturing, distribution and retail, we deliver breakthrough sleep solutions and serve the evolving needs of consumers in more than 100 countries worldwide through our fully-owned businesses, Tempur Sealy, Mattress Firm and Dreams. Our portfolio includes the most highly recognized brands in the industry, including Tempur-Pedic®, Sealy®, Stearns & Foster®, and Sleepy’s®, and our global omni-channel platform enables us to meet consumers wherever they shop, offering a personal connection and innovation to provide a unique retail experience and tailored solutions.

    We seek to deliver long-term value for our shareholders through prudent capital allocation, including managing investments in our businesses. We are guided by our core value of Doing the Right Thing and committed to our global responsibility to protect the environment and the communities in which we operate. For more information, please visit www.Somnigroup.com.

    Somnigroup Investor Relations Contact
    Aubrey Moore
    Investor Relations
    Somnigroup International Inc.
    800-805-3635
    [email protected]

    SOURCE Somnigroup International

    Continue Reading

  • New 2025 Collection Arrives on Samsung Art Store – Samsung Newsroom U.K.

    New 2025 Collection Arrives on Samsung Art Store – Samsung Newsroom U.K.

    New digital exhibition delivers a curated selection of artwork from seven of the world’s top galleries to living rooms worldwide

    Samsung Art TV users gain access to fifth Art Basel digital art collection, exhibiting global reach of artists and galleries showcased

     

    Samsung Electronics Co., Ltd., global display leader and provider of the Official Art TV of Art Basel, today announced the launch of the 2025 Art Basel Miami Beach Collection, a curated digital exhibition spotlighting 24 contemporary artists who will be showcased at Art Basel Miami Beach in December, available exclusively on Samsung Art Store[1]

     

    “With the 2025 Art Basel Miami Beach collection, we wanted to bring the distinct energy of the show directly into people’s homes,” said Daria Greene, Head of Content and Curation for Samsung Art Store. “Each artwork carries its own cultural perspective, expanding the ever-growing collection we offer on Samsung Art Store.”

     

    The new 2025 Art Basel Miami Beach Collection features artwork by emerging and established artists from around the world, presented by seven of the world’s top galleries — Instituto de Visión, Kurimanzutto, Meredith Rosen Gallery, Nina Johnson, Vermelho, Sean Kelly and Charlie James Gallery. The hand-selected digital collection reflects the cultural richness and diverse voices that define contemporary art today.

     

    Highlights include:

     

    • Olinda Silvano, “Energía de la visión de Ayahuasca” (2022)
    • The Pérez Bros., “Victoria Park” (2025)
    • George Nelson Preston, “Apenas Cinco Semanas Da Kissama e as Colinas Do Brasil Nos Surpreenderam” (2019)
    • Jennifer Rubell, “40 Hearts” (2018)
    • Aycoobo, “Luna Ilena” (2024)

     

    This is the fifth Art Basel digital art collection featured on Samsung Art Store. As part of Samsung’s longstanding partnership with the show, each collection aims to reflect the global reach of artists and galleries showcased at Art Basel, bringing that discovery directly into homes worldwide across the Samsung 2025 TV lineup.

     

    “Art Basel’s partnership with Samsung continues to expand the ways in which our galleries and artists can reach new audiences,” said Vincenzo de Bellis, Chief Artistic Officer and Global Director of Art Basel Fair. “By bringing a curated selection from Art Basel Miami Beach into homes around the world, this initiative extends the fair’s artistic vision beyond the halls of the convention center and broadens the possibilities for discovery, engagement and visibility. We are delighted to see these works presented on Samsung Art Store, reflecting the depth of our exhibitors, the global resonance of their artists and the evolving formats through which contemporary art is experienced today.”

     

    Samsung has led the global TV market for 19 consecutive years[2], delivering the exceptional picture quality that fine art demands. Samsung Art Store features more than 4,000 works by over 800 artists, including the 2025 Art Basel Miami Beach Collection.

     

    For more information, visit http://www.samsung.com/uk

     

    [1]Art Store subscription and Samsung Account connection required to access full selection of artwork.

    [2]Source: Omdia, Feb-2025 (Results are not an endorsement of Samsung)

    Continue Reading

  • Access Denied


    Access Denied

    You don’t have permission to access “http://www.afreximbank.com/fg-gold-afc-and-afreximbank-achieve-financial-close-on-us330-million-senior-debt-financing-for-baomahun-gold-project/” on this server.

    Reference #18.cc8c655f.1764588211.a441deb3

    https://errors.edgesuite.net/18.cc8c655f.1764588211.a441deb3

    Continue Reading

  • IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

    IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

    • B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, respectively
    • Deep and durable regressions observed with IDE034 monotherapy in multiple preclinical in-vivo models with B7H3 and PTK7 co-expression
    • Enhanced durability with IDE034 and IDE161 PARG inhibitor combination in preclinical in vivo models; targeting to share additional preclinical data supporting mechanistic rationale at a medical conference in H1 2026

    SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 1, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody-drug conjugate (ADC).  IDEAYA expects to begin enrolling the study in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck and ovarian/gynecological cancers.  Based on the Human Protein Atlas database, B7H3/PTK7 has been reported to be co-expressed in lung, colorectal, and head and neck cancers at approximately 30%, 46% and 27%, respectively.

    “IND clearance for IDE034 is an important step in expanding our potential first-in-class TOP1 ADC clinical pipeline into bispecific, precision-guided approaches,” said Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer of IDEAYA Biosciences. “IDE034 has demonstrated robust antitumor activity and selective targeting of B7H3- and PTK7-expressing solid tumor models. The high prevalence of B7H3/PTK7 co-expression in solid tumors such as lung, colorectal, and head and neck cancers underscores its broad indication potential.”

    “We are excited to advance our differentiated clinical strategy with now three potentially first-in-class clinical-stage programs focused on enhancing the efficacy of TOP1 ADCs through the PARG DDR combination mechanism.  We believe this approach addresses a key unmet need by improving the durability of response to TOP1 payload-based ADC therapies.  We are targeting to share additional preclinical data to support the PARG and TOP1 ADC combination rationale at a major medical conference in H1 2026,” said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.

    Preclinical studies have demonstrated strong anti-tumor activity in B7H3/PTK7-positive tumor models, including deep and durable tumor regressions with IDE034 monotherapy, supporting advancement into clinical development. This co-expression pattern supports the potential for broad monotherapy activity, while the TOP1 payload provides a strong mechanistic rationale for combining IDE034 with IDEAYA’s PARG inhibitor, IDE161.  TOP1 inhibition induces replication stress and DNA damage, which can increase reliance on the PARG pathway; therefore, a IDE034 and IDE161 combination approach may enhance anti-tumor activity in patients with solid tumors that co-express B7H3 and PTK7, consistent with the results that were observed preclinically with this combination.

    About IDEAYA Biosciences

    IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

    Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to: (i) the timing of the initiation of and enrollment of subjects for  the Phase 1 clinical trial to evaluate IDE034; (ii) the potential frequency of B7H3/PTK7 co-expressed in solid tumors types, including lung, colorectal, and head and neck cancers; (iii) the potential therapeutic benefit of IDE034 as monotherapy and in combination with IDE161, a PARG inhibitor; and (iv) the timing of a data presentation related to the  IDE034 and IDE161, PARG inhibitor, combination at a medical conference.  Preclinical study results are not necessarily predictive of future clinical trial results and/or approval.  Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA’s ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA’s Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

    Investor and Media Contact
    Joshua Bleharski, Ph.D.
    Chief Financial Officer 
    [email protected]

    SOURCE IDEAYA Biosciences, Inc.

    Continue Reading

  • Open Banking goes live in New Zealand

    Open Banking goes live in New Zealand

    Regulated Open Banking has gone live in New Zealand as part of a phased rollout, “opening the door” to faster loan approvals, easier bill management, and personalised budgeting insights, according to Commerce and Consumer Affairs Minister Scott Simpson.

    Open Banking in the country is supported by a set of regulations established under the Customer and Product Data Act 2025.

    Released in October, the regulations require the four major banks – ANZ, ASB, BNZ and Westpac – to have certain Open Banking systems ready by 1 December 2025, while Kiwibank will need to be ready by June 2026 for payments, and by December 2026 for other Open Banking services.

    “From budgeting tools to faster mortgage comparisons and low-cost payment options, the opportunities and innovations presented by Open Banking are endless,” Simpson said.

    “Open Banking makes it easier to switch banks by giving customers a safe, regulated way to share their financial information.

    “It will make mortgage applications faster by allowing third-party services to securely gather the right financial documents in one place, especially helpful for people with accounts across different banks.”

    The Minister also pointed to the benefits for small businesses in New Zealand.

    “Small businesses will also benefit from more choice in financial management and invoicing tools, helping them get paid faster and access innovative, lower-cost payment solutions,” he said.

    The Ministry of Business, Innovation and Employment (MBIE), which is providing regulatory oversight of the regime, is accepting applications from organisations that want to become accredited data requestors. In turn, they will receive an ‘accreditation mark’ from MBIE to show they are trusted and verified.

    Simpson said: “The regulations, released in October, align with global best practice and build on successful models in Australia and the UK, where Open Banking has sped up home loan approvals and enabled new consumer-friendly apps.

    “Importantly, the regulations ensure that security of consumer data is paramount. Data can only be shared under the customer’s explicit consent, and third-party requestors (such as fintechs) must be accredited by the Ministry of Business, Innovation and Employment.”

    Further reading: Westpac NZ becomes first bank to hit key Open Banking milestone

    Continue Reading

  • PIF and its commercial paper programs earn S&P’s A-1 short-term credit rating with stable outlook – Public Investment Fund

    1. PIF and its commercial paper programs earn S&P’s A-1 short-term credit rating with stable outlook  Public Investment Fund
    2. Report: Public Investment Fund Low on Cash for Future Investments  esportsadvocate.net
    3. Saudi Arabia’s PIF reportedly short on fresh capital for new investments  PocketGamer.biz
    4. After EA Deal, Saudi Arabia’s PIF Reportedly Having Cash Problems  GameSpot
    5. Saudi Arabia is reportedly running low on cash for investments following EA deal  Video Games Chronicle

    Continue Reading